• Asian Pacific Journal of Cancer Prevention
• /
• 제16권7호
• /
• pp.2915-2921
• /
• 2015

Background: Some recent clinical trials have been conducted to evaluate a combination of EGFR- TKI with chemotherapy for advanced NSCLC patients as second-line therapy, but the results on the efficacy of such trials are inconsistent. The aim of this meta-analysis was to evaluate the efficacy and safety of combination of EGFR-TKI and chemotherapy for patients with advanced NSCLC who failed first-line treatment. Materials and Methods: We searched relative trials from PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, Cochrane Library and Clinical Trials.gov. Outcomes analyzed were overall response rate (ORR), progression- free survival (PFS), overall survival (OS) and major toxicity. Results: Seven trails eventually were included in this meta-analysis, covering 1,168 patients. The results showed that the combined regimen arm had a significant higher ORR (RR 1.76 [1.16, 2.66], p=0.007) and longer PFS (HR 0.75 [0.66-0.85], p<0.00001), but failed to show effects on OS (HR 0.88 [0.68-1.15], p=0.36). In terms of subgroup results, continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance confered no improvement in ORR (RR 0.95 [0.68, 1.33], p=0.75) and PFS (HR 0.89[0.69, 1.15], p=0.38), and OS was even shorter (HR1.52 [1.05-2.21], p=0.03). However, combination therapy with EGFR-TKI and chemotherapy after failure of first-line chemotherapy significantly improved the ORR (RR 2.06 [1.42, 2.99], p=0.0002), PFS (HR 0.71 [0.61, 0.82], p<0.00001) and OS (HR 0.74 [0.62-0.88], p=0.0008), clinical benefit being restricted to combining EGFR-TKI with pemetrexed, but not docetaxel. Grade 3-4 toxicity was found at significantly higher incidence in the combined regimen arm. Conclusions: Continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance should be avoided. Combination therapy of EGFR-TKI and pemetrexed for advanced NSCLC should be further investigated for prognostic and predictive factors to find the group with the highest benefit of the combination strategy.

• 대한수의학회지
• /
• 제44권1호
• /
• pp.49-55
• /
• 2004

The present study was carried out to investigate the potential acute toxicity of CKD-602 by a single intravenous dose in Beagle dogs. The test chemical was administered intravenously to male and female Beagle dogs at dose levels of 0.3, 0.5, or 2.5 mg/kg. Mortalities, clinical findings, and body weight changes were monitored for the 14-day period following the administration. At the end of 14-day observation period, all animals were sacrificed and complete gross postmortem examinations were performed. All males and females of the 2.5 mg/kg dose group were found dead between the fourth and seventh day after the injection. Treatment related clinical signs, including vomiting, anorexia, mucous stool, diarrhea, and no stool were observed. Decrease or suppression of body weight was observed in a dose-dependent manner. In autopsy, dark red discoloration of the gastrointestinal tract, atrophy of the thymus, paleness of the spleen, sporadic dark red spots of the lung and petechia of the heart were observed in dead animals of the 2.5 mg/kg dose group. There were no specific adverse effects on males and females of the 0.3 and 0.5 mg/kg dose groups, except for the transient clinical signs such as anorexia, vomiting, and mucus/no stool. On the basis of the results, it was concluded that a single intravenous injection of CKD-602 to Beagle dogs resulted in increased incidence of abnormal clinical signs and death, decreased body weight, and increased incidence of abnormal gross findings. The absolute toxic dose of this chemical was 2.5 mg/kg for both genders. The $LD_{50}$ value was 1.1 mg/kg (95% confidence limit not specified) for both genders. The no-observed-effect level (NOEL) was considered to be below 0.3 mg/kg for both genders.

• 대한수의학회지
• /
• 제46권3호
• /
• pp.215-224
• /
• 2006

In order to search the availability of the lectin extracted from Korean mistletoe(Viscum album coloratum) as an adjuvant for the avian vaccines, attempts were made to determine toxicity of the lectin in chicks and its immunostimulating activity on the inactivated vaccines against Newcastle disease virus(NDV). For the determination of toxicity, the lectin was injected into the thigh muscle of SPF chicks(Charles River) of 1-week-old and observed hematologically and pathologically. For the determination of immunostimulating effects, lectin-adjuvanted, inactivated NDV vaccines were injected into the thigh muscle of SPF chicks in the same age group. Sera of the chicks were examined for the hemagglutination-inhibition(HI) antibodies induced, their HI titers and reaction to the NDV antigens. The data were further compared with those from aluminum hydroxide [$Al(OH)_3$]-adjuvanted vaccines and vaccines without adjuvant, and the results are as follows. There were no significant changes observed in the values of RBC, WBC, Hb, PCV, MCV, MCH, MCHC, AST, ALT, BUN, creatinine and total proteins in the chicks administered with lectin of 1.1, 2.2 and $22.2{\mu}g/kg$ body weight, which means the lectin has no effects on blood values and functions of liver and kidney. In histopathologic observation, no lesions were observed in the brain, heart, liver, lung, spleen, kidney, thymus and bursa of Fabricius of the chicks administered with lectin of 1.1, 2.2 and $22.2{\mu}g/kg$ body weight. There were inflammatory lesions, such as congestion, hemorrhage, edema, infiltration of macrophages and coagulation necrosis observed in the thigh muscle of chicks administered with lectin of $22.2{\mu}g/kg$ body weight, whereas no changes were observed in 1.1 and $22.2{\mu}g/kg$ lectin administered chicks. In chicks immunized with lectin($4.4{\mu}g/kg$ of body weight)-adjuvanted B1, LaSota and Ulster 2C vaccines, HI titers in reciprocal values for $log_2$ were 1.8-2.2 at 1 week after vaccination, which was similar with those of 1.5-2.9 by $Al(OH)_3$-adjuvanted vaccines. The HI titers by the lectin-adjuvanted vaccines reached to 3.9-5.3 at 4 weeks, whereas those by the $Al(OH)_3$-adjuvanted vaccines were more high as 7.3-9.3. Meanwhile, the immunostimulating effects of the lectin were recognized while compared to the HI titers with 2.4-3.7 in chicks immunized with vaccines without adjuvants at 4 weeks after vaccination. The chicks immunized with lectin-adjuvanted vaccines were enough to resist challenges by Kyojeongwon strain, a very virulent NDV at 4 weeks after vaccination as well as chicks immunized with $Al(OH)_3$-adjuvanted vaccines. The HI titers by the lectin-adjuvanted vaccines reached to high level as 8.7-10.3 as those with 8.2-9.6 by the $Al(OH)_3$-adjuvanted vaccines at 6 weeks after vaccination, which may be the booster effects by the challenge virus. Antibodies specific to the HN and F antigens of NDV were observed in the sera of both chicks immunized with lectin-adjuvanted vaccines and $Al(OH)_3$-adjuvanted vaccines.

• 한국약용작물학회지
• /
• 제15권6호
• /
• pp.411-416
• /
• 2007

본고에서는 초고압 추출 공정을 통한 홍경천의 독성 저감 및 항암활성 효과를 알아보기 위하여 실험을 실시하였는데 그 결과는 아래와 같다. 인간의 정상 신장세포인 HEK293을 이용한 세포 독성은 초고압으로 15분간 처리한 것에서는 1.0 $mg/m{\ell}$의 농도에서 최고 20.4%의 세포독성을 보였으며, 초고압으로 5분간 처리한 것은 22.5%로 초고압 시간이 길어질수록 세포독성이 낮아지는 것을 확인했다. 일반 추출물은 25.3%로 초고압 처리한 군에 비해 높은 독성을 나타내어 초고압 처리 시 독성이 저감되는 것을 확인하였다. 초고압 처리 군은 또한 HEL299를 이용한 세포독성 실험에서도 1.0 $mg/m{\ell}$의 농도에서 일반 추출물인 WE보다 5% 정도 낮은 독성을 나타냈다. 항암활성 측정은 A549, AGS, MCF-7, Hep3B의 암세포를 실험에 사용하여 실시하였다. 모든 암세포에서 1.0 $mg/m{\ell}$의 농도에서 75% 이상의 높은 억제활성을 보였고, 또한 암세포의 생육활성에 대한 정상 세포의 세포독성의 비로 나타낸 선택적 사멸도는 0.6 $mg/m{\ell}$에서 가장 높은 수치를 보였는데 모두 4이상으로 나타났으며, 15분 동안 초고압 추출을 한 것이 가장 높게 나타났다. 본 실험 결과를 통하여 초고압으로 인해 기존의 추출 방법으로는 추출되지 않았던 유용생리활성 물질들이 초고압으로 인해 조직과 세포막 파괴로 인해용출량 증가로 인해 수율이 증가하였으며, 홍경천의 독성 물질이 파괴되는 것으로 판단된다. 단순한 침전 추출법에 의한 추출방법보다는 초고압 추출에 의한 추출로 식물체에 함유되어 있는 성분 추출의 수율을 배가 시킬 수 있으며, 홍경천 자체 성분에 약간의 변화를 가할 수 있을 것으로 생각된다. 홍경천 성분의 변화는 초고압 추출을 통하여 에너지 수준이 제한된 수소결합, 전기적 결합, 반데르발스결합, 수소결합과 같은 약한 결합들이 분리됨으로써 성분의 변화가 있을 것으로 보인다.

• Radiation Oncology Journal
• /
• 제33권4호
• /
• pp.284-293
• /
• 2015

Purpose: To determine failure patterns and survival outcomes of T4N0-1 non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. Materials and Methods: Ninety-five patients with T4N0-1 NSCLC who received definitive radiotherapy with or without chemotherapy from May 2003 to October 2014 were retrospectively reviewed. The standard radiotherapy scheme was 66 Gy in 30 fractions. The main concurrent chemotherapy regimen was $50mg/m^2$ weekly paclitaxel combined with $20mg/m^2$ cisplatin or AUC 2 carboplatin. The primary outcome was overall survival (OS). Secondary outcomes were failure patterns and toxicities. Results: The median age was 64 years (range, 34 to 90 years). Eighty-eight percent of patients (n = 84) had an Eastern Cooperative Oncology Group performance status of 0-1, and 42% (n = 40) experienced pretreatment weight loss. Sixty percent of patients (n = 57) had no metastatic regional lymph nodes. The median radiation dose was EQD2 67.1 Gy (range, 56.9 to 83.3 Gy). Seventy-one patients (75%) were treated with concurrent chemotherapy; of these, 13 were also administered neoadjuvant chemotherapy. At a median follow-up of 21 months (range, 1 to 102 months), 3-year OS was 44%. The 3-year cumulative incidences of local recurrence and distant recurrence were 48.8% and 36.3%, respectively. Pretreatment weight loss and combined chemotherapy were significant factors for OS. Acute esophagitis over grade 3 occurred in three patients and grade 3 chronic esophagitis occurred in one patient. There was no grade 3-4 radiation pneumonitis. Conclusion: Definitive radiotherapy for T4N0-1 NSCLC results in favorable survival with acceptable toxicity rates. Local recurrence is the major recurrence pattern. Intensity modulated radiotherapy and radio-sensitizing agents would be needed to improve local tumor control.

• Environmental Analysis Health and Toxicology
• /
• 제18권2호
• /
• pp.121-129
• /
• 2003

Pendimethalin [N-(1-ethyl-propyl)-2, 6-dinitro-3, 4-xylidine, $C_{13}$H$_{19}$N$_3$O$_4$, M.W. = 281.3, CAS No. 40481-42-1]는 제초제의 일종으로, 본 연구에서는 박테리아 복귀 돌연변이 시험과 포유동물 세포를 이용한 염색체 이상 시험 및 마우스를 이용한 in vivo 소핵 시험을 수행하여 pendimethalin의 유전독성을 평가하였다. 박테리아 복귀 돌연변이 시험에서 pendimethalin은 Salmonella thphimurium TA98, TA1537 균주의 경우, 대사 활성계 존재와 부재시,TA100의 경우는 대사 활성계 부재시에만 313∼5,000 $\mu\textrm{g}$/p1a1e의 범위에서 농도의존적인 돌연변이율의 증가를 보여주었고, TA1535의 경우에는 대사 활성계 존재시 약간의 돌연변이가 증가되는 것을 관찰할 수 있었다. 그러나 대사 활성계 부재시 TA1535와 대사 활성계 존재시 TA100균주의 경우에는 돌연변이 유발능을 관찰할 수 없었다. 한편 포유동물 세포인 Chinese hamster lung(CHL) fibroblast를 이용한 염색체 이상 시험에서 pendimethalin은 대사 활성계 존재 및 부재시 2.32∼9.28 $\mu\textrm{g}$/ml 농도에서 clastogenicity를 보이지 않았다. 또한 203∼810 mg/kg의 pendimethalin을 구강 투여한 마우스의 골수세포를 이용한 in vivo소핵 시험의 결과에서도 통계적으로 유의한 소핵 유발능을 관찰할 수 없었다.다.

• Tuberculosis and Respiratory Diseases
• /
• 제43권4호
• /
• pp.637-644
• /
• 1996

만성 C형 간염환자에서 IFN으로 치료중에 발생된 간질성 폐렴은 매우 드물고 아직까지국내에는 보고된 바 없었다. 저자들은 만성 C형 간염환자가 IFN-${\alpha}$를 투여받던 중에 기침과 호흡곤란을 주소로 내원하여 간질성 폐렴으로 진단된 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• 한국약용작물학회지
• /
• 제12권4호
• /
• pp.309-314
• /
• 2004

Echinacea의 추출물 및 분획물들의 정상세포에 대한 세포독성을 측정한 결과, 0.5 mg/ml이상의 농도에서 정상세포의 생육이 20% 가까이 저해되었으며, 비교적 높은 농도인 1.0 mg/ml의 농도에서도 70%이상의 세포 생존을 나타내었다. 유방암 세포주인 MCF7에 대한 생육억제 활성은 0.5 mg/ml의 농도에서 물 추출물의 butanol 획분과 ethanol 추출물의 ethyl acetate 획분에서 각각 87%와 81%로 가장 높은 억제활성을 나타내었으며, 인간 간암세포주인 Hep3B에 대한 생육억제능은, 물과 ethanol 추출물의 butanol 획분에서 0.5 mg/ml의 농도에서 81%와 63%의 생육 억제능을 나타내었으며, 1.0 mg/ml의 농도에서는 수층획분을 제외하고는 대부분 70% 이상의 높은 생육억제능을 나타내었다. 위암세포인 AGS의 경우 물 추출물의 butanol 획분에서 0.5 mg/ml의 농도에서 80%의 높은 억제율을 나타내었으며, 1.0 mg/ml의 농도에서는 각 추출물의 수층 획분과 ethanol 추출물의 ethyl acetate 획분을 제외하고는 80% 이상의 높은 생육억제 활성을 나타내었다. 폐암세포인 A549에 대한 생육억제능은 물과 ethaonl 추출물의 butanol 획분에서 1.0 mg/ml의 농도에서 92%와 87%로 높게 나타났다. 이전까지 Echinacea에 관해서 보고된 것은 그리 많지 않으며, 본 논문에서 Echinacea의 추출물 및 분획물들에 관해 실험한 내용에 관한 것은 전무한 것으로 사료되어져, 이용에 있어서 본 논문에서 실험한 결과를 바탕으로 Echinacea의 항암활성 효과를 통하여 앞으로의 이용에 다양하게 이용될 수 있음을 알린 것이며, 아울러 Echinacea의 추출물들을 이용시 본 눈문에서 실험한 결과물인 물과 ethanol 추출물 모두 butanol 분획에서 그 효과가 가장 높았으므로 이를 사용한 다양한 암세포 사멸효과뿐만이 아니라 면역 활성 증진 및 여러 생리활성의 이용에 사용되도록 하여야 할 것이다.

• Radiation Oncology Journal
• /
• 제31권4호
• /
• pp.239-246
• /
• 2013

Purpose: We explored whether the deep inspiration breath hold (DIBH) technique using Abches during left-sided breast irradiation was effective for minimizing the amount of radiation to the heart and lung compared to free breathing (FB). Materials and Methods: Between February and July 2012, a total of 25 patients with left-sided breast cancer underwent two computed tomography scans each with the DIBH using Abches and using FB after breast-conserving surgery. The scans were retrospectively replanned using standardized criteria for the purpose of this study. The DIBH plans for each patient were compared with FB plans using dosimetric parameters. Results: All patients were successfully treated with the DIBH technique using Abches. Significant differences were found between the DIBH and FB plans for mean heart dose (2.52 vs. 4.53 Gy), heart V30 (16.48 vs. $45.13cm^3$), V20 (21.35 vs. $54.55cm^3$), mean left anterior descending coronary artery (LAD) dose (16.01 vs. 26.26 Gy, all p < 0.001), and maximal dose to $0.2cm^3$ of the LAD (41.65 vs. 47.27 Gy, p = 0.017). The mean left lung dose (7.53 vs. 8.03 Gy, p = 0.073) and lung V20 (14.63% vs. 15.72%, p = 0.060) of DIBH using Abches were not different significantly compared with FB. Conclusion: We report that the use of a DIBH technique using Abches in breathing adapted radiotherapy for left-sided breast cancer is easily feasible in daily practice and significantly reduces the radiation doses to the heart and LAD, therefore potentially reducing cardiac risk.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권5호
• /
• pp.1863-1867
• /
• 2012

Background: Maintenance chemotherapy is one strategy pursued in recent years with intent to break through the chemotherapy plateau for advanced non-small cell lung cancer (NSCLC). However, given the toxicity, platinum-based combinations are rarely given for this purpose. We carried out the present prospective study of triplet platinum-based combination sequential chemotherapy in advanced NSCLC to investigate if patients could tolerate and benefit from such intensive treatment. Methods: From Dec 2003 to Dec 2007, 190 stage IIIB and IV NSCLC patients in Sun yat-sen University sequentially received the 3 platinum-based combination (TP-NP-GP) treatment (T: paclitaxol175$mg/m^2$ d1; N: vinorelbine25$mg/m^2$ d1 and 8; G: gemcitabine1$g/m^2$ d1 and 8; P: cisplatin20$mg/m^2$ d1-5; repeated every 3 weeks). Patients were followed up to at least 3 years to obtain survival data. Treatment toxicities and the quality of life (QOL) were assessed during the whole treatment. Results: There were 187 patients evaluable. The TP, NP and GP response rates with sequential use were 42.8% (80/187), 41.1% (65/158) and 28.8% (21/73) respectively. Median survival time was 18.2 months and the 1, 2 and 3 year overall survival (OS) rates were 78.7%, 38.5% and 21.3%. Patients receiving > 6 cycles of chemotherapy had significantly longer OS and TTP (MST 25.3 vs. 14.5 months, TTP 15.1 vs. 9.1 months). The QOL on the whole for the patients was improved after chemotherapy. Conclusions: The sequential chemotherapy strategy with triplet platinum-based combination regimens can improve the survival outcome and the quality of life of advanced non-small cell lung cancer patients.